Lecanemab Phase 2B Study

Eisai Presents New Data from Lecanemab Phase 2B Study

For Early Alzheimer's Disease in Late-Breakers and Pipeline Updates at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference